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Abstract
Clear documentation of literature search and presentation methodologies can improve
transparency in chemical hazard assessments. We sought to improve clarity for the scientific
support for cancer mechanisms of action using a systematic approach to literature retrieval,
selection, and presentation of studies. The general question was “What are the mechanisms by
which a chemical may cause carcinogenicity in the target tissue?” Di(2-ethylhexyl)phthalate was
used as a case study chemical with a complex database of >3,000 publications. Relevant
mechanistic events were identified from published reviews. The PubMed search strategy included
relevant synonyms and wildcards for DEHP and its metabolites, mechanistic events, and species
of interest. Tiered exclusion/inclusion criteria for study pertinence were defined, and applied to the
retrieved literature. Manual curation was conducted for mechanistic events with large literature
databases. Literature trees documented identification and selection of the literature evidence. The
selected studies were summarized in evidence tables accompanied by succinct narratives. Primary
publications were deposited into the Health and Environmental Research Online (http://
hero.epa.gov/) database and identified by pertinence criteria and key terms to permit organized
retrieval. This approach contributes to human health assessment by effectively managing a large
volume of literature, improving transparency, and facilitating subsequent synthesis of information
across studies.
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Toxicological reviews conducted in support of US Environmental Protection Agency’s
Integrated Risk Information System (IRIS) summarize information about potential adverse
health effects from long-term chemical exposures, and provide a scientific basis for
Agency’s decisions supporting risk management in the protection of public health. IRIS
toxicological reviews address both cancer and noncancer hazards of environmental
contaminants and include descriptive and quantitative information about known or possible
adverse health effects. The critical examination of a large body of evidence is necessary to
understand health outcomes from chemical exposures, underscoring the importance of the
quality and transparency of the systematic literature review and evidence presentation.
Indeed, as has been pointed out by several National Research Council (NRC) committees
(NRC, 2009; NRC, 2010; NRC, 2011), comprehensive and logically-organized evidence
presentation is essential for clearly describing the scientific evidence in support of
conclusions about chemical hazard(s) and the related mechanisms of action.
The challenge of characterizing the evidential support for decision-making has been best
addressed in the field of evidence-based medicine wherein a systematic approach to
determining the quality of evidence and the strength of a particular recommendation has
been adopted (Drummond et al., 2008; Guyatt et al., 2012b). Approaches such as GRADE
(Grading of Recommendation Assessment, Development and Evaluation) require clear
specification of a study question, and outline suggestions for tabular presentation of
evidence (Guyatt et al., 2012a; Guyatt et al., 2011). Other methodologies include the
Institute of Medicine approach (IOM, 2008) of an analysis framework for evaluating
exposures incurred during military service and the contribution to disease in armed forces
personnel. Approaches for causal inference, hierarchies for classifying strength of evidence,
and for reporting meta-analyses are also hallmarks of reports that guide public health
decision-making (DHHS, 2004; Stroup et al., 2000). The CAMARADES (Collaborative
Approach to Meta-Analysis and Review of Animal Data from Experimental Studies)
initiative, for example, seeks to address sources of bias affecting the validity of animal
studies and hence translation of the results to the clinic (e.g., of candidate drugs) (van der
Worp et al., 2010). However, the evidence base for supporting medical decisions, including
clinical trials of intentional exposures to potential therapeutics, differs greatly from that
typically used in assessing hazards of environmental or occupational exposures to
chemicals. An adaption of the evidence-based medicine approach for environmental health
has been proposed, focusing on the following critical aspects: 1) clearly defining the study
question, and 2) documenting the evidence collection and decision-making processes,
including the criteria and rationale for each choice (Woodruff and Sutton, 2011). Together,
these serve as a guide for human health assessments of chemicals, with particular regard to
transparency and documentation of evidence selection.
The NRC recommends several strategies for enhancement of clarity and transparency in
evidence evaluation for environmental chemicals (NRC, 2009; NRC, 2010; NRC, 2011). For
extensive databases, tabular presentation of the evidence is recommended to clarify what
data are available for the chemical and its metabolites, including mechanistic events, species
of interest, dose or concentration spacing, replicates and variability, and experimental details
and results. Graphical tools, such as flow diagrams, further aid documentation of evidence
capture, selection, and evaluation. Finally, public access to the systematically organized
literature used to draw conclusions is needed.
In accord with the NRC guidance for improving evaluation for environmental chemicals, we
aimed to devise an approach that can be applied to a systematic search, identification, and
presentation of the mechanistic evidence on chemical hazards, and that would provide
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succinct and informative tabular presentation of key studies and their findings in support of
human health assessment decisions. We explored as a case example the mechanistic events
potentially involved in liver carcinogenesis by di(2-ethylhexyl)phthalate (DEHP), a
chemical with a voluminous and complex database of mechanistic studies. The multi-step
strategy applied herein was designed to address this particular topic and may not be
applicable to every target tissue and/or chemical. Additionally, this strategy intends to
address only the initial steps of the systematic process necessary to synthesize and interpret
a mechanistic evidence database, with subsequent aspects focusing on individual study
quality evaluations, sensitivity analyses, and weighing of the various evidence components.
Nonetheless, we posit that clear definition of the study question, followed by
implementation of a comprehensive, integrative, and clear selection and presentation process
for mechanistic evidence will result in improved clarity of the scientific support used for risk
evaluations related to environmental chemicals.
2. Methodology
2.1. Specification of the study question
Figure 1 presents a workflow of the systematic approach detailed below. In Step 1, a clearly
specified study question is identified to focus the literature search strategy. For this case
study, the general question was “What are mechanisms by which chronic exposure to the
chemical (DEHP) may cause carcinogenicity in the target tissue (liver)?” For each
mechanistic event, this question was then divided into three subparts. (i) Does the
mechanistic event occur with DEHP exposure in humans or cells of human origin? (ii) Does
the mechanistic event occur with DEHP exposure in experimental animals including rodents
or other species (e.g., non-human primates)? (iii) Does the mechanistic event contribute to
DEHP hepatocarcinogenicity? The question, including its subparts, was framed such that the
pertinence of the evidence applicable to DEHP, liver cancer and the particular mechanistic
event of interest could be evaluated.
The significance of this study question for assessing the overall health hazard of DEHP is
based on multiple reports of hepatocarcinogenicity in two rodent species and both sexes
upon chronic exposure (Melnick et al., 1987). Additionally, the liver is among the more
sensitive target organs in which the carcinogenicity of DEHP has been identified in rodents.
Differing conclusions have been reached about the potential relevance of the liver tumor
findings to humans. In contrast to the 2000 IARC conclusions regarding the carcinogenic
risks of DEHP (IARC, 2000), the 2011 IARC Monographs Working Group evaluating
DEHP concluded that “the human relevance of the molecular events leading to DEHP-
induced cancer in several target tissues (e.g., liver and testis) in rats or mice could not be
ruled out, resulting in the evaluation of DEHP as a Group 2B agent [possibly carcinogenic to
humans], rather than Group 3 [not classifiable as to its carcinogenicity to humans]” (Grosse
et al., 2011, IARC, 2012). For these reasons, the question of how DEHP may be associated
with liver carcinogenicity could be informative of both qualitative and quantitative
conclusions in assessing its relevance to human cancer hazard. We focused on the use of a
systematic approach for review of the literature database on this important topic.
Similar to the present DEHP example, study questions concerning issues relevant to health
hazard decision-making may be raised for other chemicals with voluminous literature in the
course of nomination or evaluation for health hazard assessment by EPA, other federal
agencies, other organizations, or the public. Target tissue-specific questions may be framed
based on detection of the chemical in the human body, indications of human health
relevance, or indications of environmental contamination (NRC, 1991). These questions
may also be informed by exposure-specific information on human populations at various
lifestages.
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2.2. Identification of relevant mechanisms of action
Most environmental chemicals are thought to operate through multiple mechanisms and the
challenge of comprehensive review in the overall evaluation of mechanistic evidence has
been considered (Gehlhaus et al., 2011; Guyton et al., 2008). For this work, we constructed a
comprehensive list of likely potential mechanisms of DEHP-induced liver carcinogenesis
from reviews on the mechanisms of DEHP liver effects published by a diverse author set
(Caldwell, 2012; Guyton et al., 2009; Klaunig et al., 2003; Peters et al., 2005; Roberts et al.,
2007; Rusyn and Corton, 2012; Rusyn et al., 2006; Melnick, 2001; McKee, 2000). We
considered reviews published since the release of the 2000 IARC monograph on DEHP
(IARC, 2000), and selected recent, as well as highly cited older publications.
2.3. Literature search strategy
A PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) search strategy was devised to account
for mechanistic studies that may have used either the parent compound and/or its
metabolites. In the case of DEHP, many studies have used major metabolites (e.g., mono-
ethylhexyl phthalate, MEHP) to account for rapid hydrolysis of the parent molecule in the
gastrointestinal tract (Kluwe, 1982). The search was first conducted using only “DEHP” as
the term, and the number of results, as well as the medical subject heading (MeSH)
decompositions, was recorded and dated (Table 1). To acquire mechanistic evidence for
metabolites of DEHP, we created an inclusive string of relevant search terms based on
review of recent comprehensive studies of DEHP metabolism in humans and other species
(Lorber et al., 2010; Lorber et al., 2011; Svensson et al., 2011; Teitelbaum et al., 2012). The
expanded search string was submitted to PubMed and the number of results and MeSH
subheadings recorded. MeSH subheadings were manually verified for relevance to the
search terms entered. Subheadings deemed irrelevant (e.g., not a known metabolite of
DEHP) were deleted from the PubMed query translation, the search was repeated and any
changes in results were recorded.
2.4. Literature searches, mechanisms of action
The search string for DEHP and its metabolites was expanded to incorporate the target tissue
(liver), a particular mechanistic event, and the relevant species of interest to build a literature
database of evidence. Based on the comprehensive reviews (see section 2.2), we selected
humans, non-human primates and rodents (rat or mouse) as most relevant for the purpose of
constructing the evidence tables for DEHP as a case study. We employed wildcards and
synonyms for relevant search terms to most effectively identify pertinent literature (Table 1).
As described in section 2.3, we recorded and dated PubMed query results, including MeSH
subheadings.
2.5. Application of inclusion/exclusion criteria
Table 2 lists tiered criteria by which retrieved literature was manually screened by a subject
topic expert using the full text research articles for inclusion into evidence tables pertaining
to each consensus mechanistic event. The criteria permit transparent and consistent critical
evaluation of evidence for tabular presentation. The Tier 1 criteria used in evaluating all of
the retrieved literature considered whether the publication addressed the chemical, tissue,
mechanism, and species of interest, and whether it contained original data. If a particular
mechanism of action had been a subject of many studies (e.g., the number of publications
containing original data within a category exceeded 20), additional Tier 2 criteria were
applied addressing the study’s design and reporting, such as employment of multiple doses,
inclusion of at least three biological replicates (the minimum required to conduct a statistical
t-test), reporting of experimental variability, and clarity of description of the study’s
methodology. For this case study, we considered “sufficient replicates” to be at least an N of
Kushman et al. Page 4













3 based on statistical considerations. These criteria were informed by the US EPA’s
Guidelines for Carcinogen Risk Assessment (EPA, 2005).
2.6. Construction of the literature trees
In the next step, flow diagrams we termed “literature trees” were constructed to visualize
and document how initial search findings were manually narrowed to those considered for
inclusion into the evidence tables. Beginning from the highest level of the tree, the chemical
of interest, publications that were not relevant to the target tissue, selected mechanism, or
species were removed. After excluding reviews as determined by PubMed, full text
references were then retrieved for manual consideration and inclusion into evidence tables,
with Tier 2 assessment criteria applied to large databases.
2.7. Construction of the evidence tables
Evidence tables for each potential DEHP mechanism of action in liver were constructed and
stratified in accordance with the type of experimental system(s) and other relevant
information. Representative examples of the type of information included in these evidence
tables are shown in Tables 3, 4, and 5. Data was extracted manually into Microsoft Excel
and this program was used to calculate effect as a percent change of control. If a study of
interest only presented relevant information in graphical form, the GrabIt! Excel plug-in
(www.datatrendsoftware.com) was used for extracting the quantitative information. Results
were grouped according to whether studies were conducted in vivo or in vitro, and
subsequently sorted with those testing longer duration, lower exposures presented first.
Studies that tested the relationship of the mechanistic event to an outcome by evaluating the
impact of altering, suppressing or enhancing the mechanism (e.g. in genetically-modified
animal models) were prioritized in the presentation. Information about the study could be
readily accessed via a hyperlink to the Health and Environmental Research Online (HERO)
database (http://hero.epa.gov) provided for each reference. Tables also capture the
experimental system or materials used, the number of samples tested, and any relevant
treatment periods. Marker(s) or endpoint(s) for each mechanistic event were clearly stated,
and quantitative information, where available, on the doses corresponding to the observed
changes in that endpoint was provided. Experimental results were expressed as percent
change from control and statistical , as reported by the study authors, was indicated. Results
for each potential mechanism of action relevant to each species of interest were briefly
summarized (in future applications of this strategy, those studies excluded for presentation
purposes using Tier 2 criteria may be summarized in this text or in supplemental materials),
taking into consideration the types of effects observed, consistency across studies, dose-
response relationships, and the statistical significance of effects reported by the study
authors.
2.8. Literature organization in HERO
The primary literature considered in the assessment of DEHP mechanisms of action in the
liver was uploaded and organized in the HERO database. As appropriate, references were
labeled with both the inclusion and exclusion assessment criteria, as well as other pertinent
information (e.g., species), to enhance transparency and to facilitate navigation and
searching.
3. Results
3.1. Literature search for DEHP and its metabolites
The initial search performed by entering “DEHP” into PubMed yielded a return of 2319
references (as of June 25, 2012), with MeSH subheadings all relevant to DEHP and other
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phthalates (Table 1 and Figure 2). However, some in vitro mechanistic studies may have
been conducted with DEHP metabolites, not the parent compound. Accordingly, an
expanded search string including metabolites and relevant chemical abbreviations and
prefixes (see Table 1) yielded 3361 publications (as of June 25, 2012), an increase of nearly
45%. The MeSH query translations were manually examined and terms not relevant to
DEHP metabolism (e.g., “2-methyl-5,6-cyclopentapyrimidine”) were excluded. Exclusion of
such headings did not affect the number or content of search results returned.
3.2. Identification of DEHP mechanisms of action in liver
Based on a survey of seven recent and/or highly cited reviews from diverse (in terms of
affiliation with the government, academia and/or industry sectors) authorship (Caldwell,
2012; Guyton et al., 2009; Klaunig et al., 2003; Peters et al., 2005; Roberts et al., 2007;
Rusyn and Corton, 2012; Rusyn et al., 2006, Melnick, 2001; McKee, 2000) nine mechanistic
events for DEHP in liver were identified (Figure 2). These were peroxisome proliferation,
cell proliferation, PPAR receptor activation, oxidative stress, nuclear receptor activation,
genotoxicity, apoptosis, disruption of gap junction intercellular communication, and Kupffer
cell activation. Accordingly, search phrases describing the tissue of interest, liver, and each
of the mechanistic events were composed and concatenated with the search string devised
for DEHP and its metabolites. Query translation anomalies were addressed, and irrelevant
MeSH headings were also removed. For instance, because the MeSH query translation for
liver did not include the synonym “hepatic” or any variation thereof, the wildcard “hepat*”
was included to maximize returns for relevant evidence (Table 1). An example search string
for one of the mechanistic events (peroxisome proliferation) is also shown in Table 1. Each
search string and the corresponding MeSH headings used in the final search were saved to
enable future examination of the search terms used.
3.3. Application of inclusion/exclusion criteria, construction of literature trees and
evidence tables
After collecting literature lists for each of the mechanistic events, we subjected each
reference to predefined assessment criteria (Table 2) to determine its suitability for inclusion
into an evidence table. As recommended by the NRC (2011), a literature tree was created for
each of the mechanistic events to graphically document inclusion/exclusion criteria and the
number of publications kept or removed at each step (Figures 3–5). Here, we provide several
examples illustrating the process and the format for the information entered into the
evidence tables.
“Peroxisome proliferation” is a mechanistic event with the largest literature database, where
358 publications were identified by the PubMed search (Figure 3 and Table 1). Upon
inclusion of species-specific search terms (Table 1), most references were subdivided as
relevant to humans, rodents, and non-human primates. Studies reporting results in other
species were also noted, totaling 4 references to DEHP toxicity studies in rabbits or fish.
Reviews, as identified by PubMed, were not considered further.
Next, the articles were considered for inclusion by manually examining the abstracts of each
study. As an example, of the 324 publications identified by the PubMed query as containing
information on peroxisome proliferation in rodents, 262 were excluded, most because they
were not studies of the relevant chemical (DEHP or its metabolites), tissue (liver), species
(rodents), or the mechanism of interest. Many lacked primary data, but were not indexed as
reviews by PubMed. This first manual review step was essentially a reapplication of the Tier
1 assessment criteria. A follow-up step considered the full text of each remaining
publication according to Tier 2 criteria (Table 2) and 43 additional studies were excluded for
reasons identified in Figure 3. Ultimately, 19 unique publications were selected for inclusion
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into the evidence table for peroxisome proliferation in rodents. Table 3 shows representative
tabular formatting of some of the experimental evidence. For each mechanistic event, a table
may be subdivided by species and type of study (in vivo or in vitro), with further
categorization of in vivo studies by strain, sex and study duration (chronic cancer bioassay,
subchronic or acute).
“Peroxisome proliferator activated receptor” is a mechanistic event with an intermediate-
sized literature database, where 46 publications were identified by the PubMed search
(Figure 4). Interpretation of this mechanistic event in the human health assessment of a
number of peroxisome proliferators has been controversial due to differing views as to its
relevance to humans (Klaunig et al., 2003; Melnick, 2001). Several studies that addressed
this mechanism of liver carcinogenesis have challenged the hypothesized mode of action
using knockout and transgenic (e.g., humanized) mouse strains. Table 4 provides several
representative examples of how evidence from such studies can be displayed.
“Gap junction intercellular communication” (GJIC) is representative of a mechanistic event
with a small, yet potentially important, literature database (Figure 5). Only 12 articles were
identified for GJIC. Each reference was assessed using the PubMed search through Tier 1
criteria, and a breakdown of the amount of evidence for each species of interest and whether
or not the reference contained original data was performed. At the end, 1 unique article for
humans, 5 for rodents, and 2 for non-human primates were selected for inclusion into the
evidence table for GJIC which is included in its entirety as an example (Table 5).
3.4. Short narrative summary for mechanisms of action
Succinct summaries reporting critical conclusions from the gathered evidence, and capturing
details relevant to study design, observed effects, dose-response relationships, and
consistency across various research groups can readily be generated from the evidence
tables. Concordance of the results across species may be considered here, given completion
of study selection and presentation. The paragraphs that follow provide an example of a
short narrative that can be developed from the evidence table for GJIC (provided in its
entirety as Table 5).
“In humans or other primates, no significant in vitro effects on GJIC were observed in a
single study of human hepatocytes, in a single human cell line, or in a single study of non-
human primate hepatocytes. Similarly, a single dose in vivo study in male primates did not
observe effects on GJIC following short-term treatment. No human or non-human primate
studies evaluated females or exposures longer than two weeks. The only measure of GJIC
used in these studies was in situ dye transfer (ISDT).
In rodents, only a small body of evidence suggests that chronic exposure to DEHP disrupts
GJIC. A statistically significant decrease in dye transfer of about 40% was observed in male
F344 rats after short term exposure to DEHP, and non-statistically significant decreases of
approximately 30% were observed in a single study of male rats and mice treated for 18
months. In vitro, dose-dependent significant decreases were observed across four studies
examining primary hepatocytes derived from male and female mice and two strains of male
rats, following treatments with DEHP or MEHP for up to six weeks. The only measure of
GJIC used in these studies was ISDT. Decreases in GJIC following short-term DEHP
treatment were consistent and dose-related across several studies with differing sexes,
species, or strains.
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The goal of this study was to develop and implement a systematic approach for literature
review, identification and presentation that would improve transparency of evidence
collection and standardization of reporting for human health assessment of chemical
hazards. The process detailed herein addresses critical points of guidance presented in recent
NRC reports (NRC, 2010; NRC, 2011). Specifically, we focused on the protocol for
standardization of the literature review through a systematic and transparent process, and
developed a template for presentation of reviewed studies in tabular and graphic form so that
the key dimensions of study characteristics and pertinence are clear.
A major benefit of this work includes reducing a large literature database into a smaller,
more manageable one, allowing for better analysis of the strength of evidence provided by
concordance of results across studies, species, strain, sex, dose and time of exposure as well
as endpoint assessment. The strategy has also proven effective for appraisal and synthesis of
large amounts of information, and is conducive towards visual data displays that help track
capture of results and thus facilitate decision-making processes. The workflow in the process
presented herein is also iterative such that the results from each previous step are carried
forward and built upon in the subsequent steps.
Several key features of our process directly address elements common to systematic
evidence review and evaluation. First, we selected, and provide transparent documentation
of, search terms used to identify literature describing mechanisms of action of DEHP and its
metabolites. Incorporating synonyms and wildcards representing critical terms in the
PubMed search is necessary in order to obtain the most comprehensive results possible.
Second, establishment of tiered assessment criteria for inclusion and exclusion of literature
allows for transparent and consistent critical evaluation of evidence for tabular presentation.
These criteria focus on study relevancy to the predefined research question and experimental
design. The tiered approach also effectively reduces large literature databases to manageable
ones, facilitating extraction of data for inclusion in evidence tables. As applied to selecting
pertinent mechanistic evidence for DEHP, our criteria included consideration of target
tissues, explicit identification of species and sex of animals, whether the study was in vitro
or in vivo, dosing information, and characteristic endpoints of the relevant mechanisms.
These were applied in the determination of the pertinence of the studies to the predefined
research question. We envision that subsequent steps of the evaluation could systematically
assess bias and study quality, and evaluate weight-of-evidence based upon the literature
collected and screened.
Third, visualization of the evidence inclusion and exclusion in the form of a flow diagram,
or literature tree, comprehensively documents study selection. The progression from the
initial 3361 articles identified as relevant to DEHP to those included in the mechanism-
based evidence tables is transparent, displaying how search findings are narrowed to articles
in the final review selection based upon the pre-defined criteria.
Fourth, by summarizing findings in evidence tables, the need for long descriptions of studies
for each mechanism is effectively eliminated. The tables include information about the
publication, as well as necessary experimental details and dose-response relationships, if
any. The results of statistical analyses of the findings by the authors, where applicable, were
noted. Additionally, we constructed tables in a manner that highlights significant results and
consistency of dose-response relationships in each species of interest. This is especially
useful to the mechanistic evidence evaluation, as US EPA guidance (EPA, 2005) indicates
that the strongest mechanistic evidence is provided by studies that experimentally challenge
the role of the mechanism in carcinogenesis or other adverse outcomes, in particular by
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evaluating the impact of altering, suppressing or enhancing the mechanism (e.g., in
genetically-modified or other experimental models, or in recovery experiments). The
experimental evidence included in the table of the peroxisome proliferation mechanism
provides an example addressing this critical point. Furthermore, the tabular presentation can
highlight the extent of support across experimental designs, consistent with US EPA
guidance (EPA, 2005) that conclusions are meaningfully strengthened by consistent results
in different experimental models, but not by replicate experiments in the same model.
Finally, as illustrated for GJIC disruption (for which the evidence tables is provided in
entirety in Table 5), short narratives summarizing the presented evidence can readily be
developed from the tables.
This stepwise process is also potentially informative for quantitative aspects of chemical
hazard assessment, including ranking of evidence for applicability to dose-response analysis,
or in the conduct of meta-analyses across studies, chemicals, or species. We illustrate
comparability of study results based upon experimental characteristics rather than the
direction or magnitude of outcomes, consistent with the Navigation Guide Project
supporting evidence-based decision-making in environmental health (Woodruff and Sutton,
2011). The NRC (NRC, 2011) also suggested that IRIS assessments document the rationale
by which studies are excluded or included for derivation of reference values for noncancer
endpoints and unit risks for cancer endpoints. Systematic approaches for evidence
identification and presentation may facilitate assessment of the experimental conditions and
quantitative outcomes within the referenced body of evidence. From this, we anticipate that
a formal assessment of consistency across studies, displays of variability (e.g., 95%
confidence intervals), as well as assessments of study quality, could be performed as a next
step in the evaluation.
There are, however, limitations identified through the conduct of this study. To ensure the
transparency and reproducibility of search strategies, we utilized a publicly available
database (i.e., PubMed) for identification of the evidence. Although this database is
extensive, searching it exclusively may nonetheless miss studies; thus, one of the lessons
learned applicable to future literature identification projects is the need to assess the benefit
of extending the search to other online databases (e.g., ToxNet, Web of Science, technical
study reports, or foreign-language pertinent literature sources). As an example, a search for
“DEHP and peroxisome proliferator activated receptor” using the Web of Science database
interface yielded over twice the number of references than retrieved from PubMed alone
(data not shown). The relative merits of systematically capturing mechanistic information
from “grey” literature (e.g., technical reports) or restricted-access evidence materials (e.g.,
proprietary information submitted for regulatory review by commercial entities) also need to
be explored.
Additionally, we did not attempt to retrieve studies identifying novel mechanistic events of
DEHP that had not been the subject of prior published reviews. While anticipated to be few
in numbers, those additional pertinent documents may be identified using broader search
strategies. The retrieved results can be filtered against the combined reference lists of the
published reviews to aid in identifying new mechanistic events and their associated search
terms. Finally, our literature search terms captured only DEHP-specific studies. Thus, read-
across from other chemicals (e.g., other peroxisome proliferators), tissues and life-stages
that may have an even more comprehensive database would not be picked up by our process
which makes it difficult to tackle issues such as biological plausibility or analogy to other
chemicals.
Our approach also underscores the importance of manual expert review. We found that
computerized database searches both excluded references with relevant experimental data
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and included those without primary research results (e.g., review articles). For example, we
identified articles that contained chemical-relevant experimental results that are not
explicitly described in the study abstract or methods. We also found that search strings
employed to gather the literature were not necessarily exclusive at the level of species. For
example, a study may repeatedly reference human data in the introduction and/or discussion,
but experimentally present rodent data. Additionally, because PubMed does not index all
reviews, our searches retrieved some articles that lacked original data. These examples
highlight the need for manual expert review of full text and figures, with application of
inclusion and exclusion criteria to determine the relevance of results for extraction.
We employed a quality control process involving subsequent review by one additional
expert in order to ensure correct categorization of the retrieved articles. However, in keeping
with the best practices of systematic review, we would further strengthen our approach in
the future by utilizing two independent screeners and outlining clear strategies at the outset
for resolving any conflicts encountered during critical examination of the pertinence of the
identified evidence. Our effort could also be extended to the subsequent aspects of systemic
evidence appraisal including assessment of bias and evaluation of weight-of-evidence.
Given time and resource constraints, the present effort focused on information search,
selection, and presentation, addressing about half of the key practices of systematic review
as outlined by the Cochrane Collaboration (2006).
In summary, by employing computerized retrieval of literature in PubMed, expert
consideration of articles for inclusion, and methods of evidence reporting that can be
conducted and displayed in a consistent and transparent manner, we have developed an
approach that will strengthen the validity of scientific evidence evaluations in chemical
hazard assessments. The resulting deliverables can also be included in various portions of an
IRIS Toxicological Review, with evidence tables and short narrative summaries in the
primary body of the document, and search strategies, literature trees, and assessment criteria
included in an appendix. Online resources such as the HERO database can also be utilized to
capture study information, with all of the literature considered in the assessment classified in
accordance with inclusion and exclusion criteria. Our process also allows for expert
evaluation of results at every stage, a critical component to conduct an interpretation of the
relevance of results to the assessment process. Ultimately, this systematic approach to
literature retrieval, selection, and presentation of studies effectively manages a large volume
of literature, improves transparency, and facilitates synthesis of critical information (e.g.,
regarding hepatocarcinogenicity mechanism of action) in human health assessments.
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A systematic approach to literature retrieval and inclusion/exclusion was developed
Graphical presentation of mechanistic evidence is demonstrated
Di(2-ethylhexyl)phthalate was used as a case study chemical
A complex mechanistic evidence database of >3000 publications was effectively
managed
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The 8-step systematic approach for identifying, evaluating, and presenting mechanism of
action evidence.
Kushman et al. Page 14














Consensus mechanistic events elicited by DEHP in liver and PubMed search results for sizes
of literature databases for each. The numbers represent the quantity of articles in the
databases at the level of chemical, tissue, and mechanisms of action.
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Literature tree for the “peroxisome proliferation” mechanistic event. Progression from the
initial 3361 identified articles relevant to DEHP or its metabolites to those included in the
evidence tables is shown.
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Literature tree for the “peroxisome proliferator activated receptor” mechanistic event.
Progression from the initial 3361 identified articles relevant to DEHP or its metabolites to
those included in the evidence tables is shown.
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Literature tree for the “gap junction intercellular communication” mechanistic event.
Progression from the initial 3361 identified articles relevant to DEHP and its metabolites to
those included in the evidence tables is shown.
Kushman et al. Page 18

























Kushman et al. Page 19
Table 1
Overall search strategy for DEHP, its metabolites, tissue, and representative mechanism of action and species.
Search strings, PubMed MeSH query translations, and returned results for DEHP and its metabolites, the





(user query) MeSH query translation
Chemical DEHP
“diethylhexyl phthalate”[MeSH Terms] OR (“diethylhexyl”[All Fields] AND





(mono (3- carboxypropyl) OR
mcpp OR mono (2- ethylhexyl) OR









MEHHP OR (2- carboxymethyl) OR
MECPP OR MMHP
OR (2-ethyl-5- oxyhexyl))
mono[All Fields] AND 3-carboxypropyl[All Fields] OR mcpp[All Fields] OR
mono[All Fields] AND 2-ethylhexyl[All Fields] OR mono[All Fields] AND 2-ethyl-
5-oxohexyl[All Fields] OR (“methylphosphite”[Supplementary Concept] OR
“methylphosphite”[All Fields] OR “meoph”[All Fields]) OR mono[All Fields] AND
2-ethyl-5-carboxypentyl[All Fields] OR (“2-methyl-5,6- cyclopentapyrimidine”
[Supplementary Concept] OR “2-methyl-5,6- cyclopentapyrimidine”[All Fields] OR
“mecpp”[All Fields]) OR mono[All Fields]
AND 2-ethyl-5-hydroxyhexyl[All Fields] OR (“mono-(2- ethylhexyl)phthalate”
[Supplementary Concept] OR “mono-(2- ethylhexyl)phthalate”[All Fields] OR “mehp”
[All Fields]) OR (“diethylhexyl
phthalate”[MeSH Terms] OR (“diethylhexyl”[All Fields] AND “phthalate [All Fields])
OR “diethylhexyl phthalate”[All Fields] OR “dehp”[All Fields]) OR (“2- ethylhexanol”
[Supplementary Concept] OR “2-ethylhexanol”[All Fields] OR “2 ethylhexanol”[All
Fields]) OR (“phthalic acid”[Supplementary Concept] OR
“phthalic acid”[All Fields]) OR 2-ethyl-5-hydroxyhexyl[All Fields] OR (“mono-(2-
ethylhexyl)phthalate”[Supplementary Concept] OR “mono-(2- ethylhexyl)phthalate”
[All Fields] OR “mehp”[All Fields]) OR 2-carboxymethyl[All
Fields] OR (“2-methyl-5,6-cyclopentapyrimidine”[Supplementary Concept] OR
“2-methyl-5,6-cyclopentapyrimidine”[All Fields] OR “mecpp”[All Fields]) OR
(“mono-5-methylhexylphthalate”[Supplementary Concept] OR “mono-5-
methylhexylphthalate”[All Fields] OR “mmhp”[All Fields]) OR (2[All Fields] AND
ethyl[All Fields] AND 5[All Fields] AND oxyhexyl[All Fields])
Tissue (liver) liver[MeSH Terms] OR “liver”[All Fields]
(liver OR hepat*) (“liver”[MeSH Terms] OR “liver”[All Fields]) OR (hepat[All Fields] OR ¶…)
Mechanism (peroxisome proliferation) (“peroxisomes”[MeSH Terms] OR “peroxisomes”[All Fields] OR“peroxisome”[All Fields]) AND proliferation[All Fields]
(peroxis*)
peroxis[All Fields] OR peroxiscan[All Fields] OR peroxisides[All Fields] OR
peroxismal[All Fields] OR peroxisme[All Fields] OR peroxismes[All Fields] OR
peroxismose[All Fields] OR peroxisom[All Fields] OR peroxisoma[All Fields] OR
peroxisomal[All Fields] OR *…
Species (mouse or rat) (“mice”[MeSH Terms] OR “mice”[All Fields] OR “mouse”[All Fields]) OR rat[AllFields]
(mouse OR rat OR
hamster OR rodent
OR murine OR Mus
musculus or
Rattus)
(“mice”[MeSH Terms] OR “mice”[All Fields] OR “mouse”[All Fields]) OR rat[All
Fields] OR (“cricetinae”[MeSH Terms] OR “cricetinae”[All Fields] OR
“hamster”[All Fields]) OR (“rodentia”[MeSH Terms] OR “rodentia”[All Fields] OR
“rodent”[All Fields]) OR (“mice”[MeSH Terms] OR “mice”[All Fields] OR
“murine”[All Fields]) OR (“mice”[MeSH Terms] OR “mice”[All Fields] OR
(“mus”[All Fields] AND “musculus”[All Fields]) OR “mus musculus”[All Fields])
OR (“rats”[MeSH Terms] OR “rats”[All Fields] OR “rattus”[All Fields])
¶
Wildcard search for 'hepato*' results in more than 600 variations, hence the search uses only the first 600 variations.
*
Additional ～60 MeSH terms that result from “(peroxis*)” query in PubMed are not shown.
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Table 2
Evaluation criteria used in the consideration of inclusion and exclusion of evidence for DEHP mechanisms of





(Applied to all searches)
1 Did the study evaluate effects of the chemical of interest or its metabolites known to be formed in
humans?
2 Did the study evaluate effects in the tissue (organ) of interest or cells derived from this tissue?
3 Did the study evaluate cellular, biochemical or molecular effects relevant to the mechanism under
consideration?
4 Did the study include information sufficient to determine what species werestudied?








1 Did the study employ dose-/concentration-response design?
2 Did the study contain sufficient number of replicates within each experimental group so that the
evaluation of significance of the effect was performed?
3 Did the study report variability within each experimental group/condition (for studies with continuous
data)?
4 Does the study clearly describe the experimental details (e.g., is it possible to determine what endpoint
was studied and the techniques used)?
¶
If the answer is “no” to any of these criteria questions, the study will be excluded from the evidence table.
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